Craig-Hallum Maintains Buy on Bioventus, Raises Price Target to $16
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Craig-Hallum analyst Alexander Nowak maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $16.
Craig-Hallum analyst Alexander Nowak maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $16.